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Undergoing Upfront Autologous Stem Cell Transmplant
Parneet K. Cheema, Sahar Zadeh, Vishal Kukreti, Donna Reece, Christine Chen,
Suzanne Trudel, Joseph MikhaelMultiple myeloma (MM) rarely occurs in patients 40 years of age and younger. This young age has been
reported to correlate with improved survival in patients with MM. The objective of this study is to describe
presenting features and outcomes of patients#40 years of age with MM who undergo autologous stem cell
transplantation (ASCT) as first-line treatment, and compare overall survival (OS) and progression free sur-
vival (PFS) to patients aged 41-65 years.We performed a retrospective institutional review of all patients#40
years of age and 41-65 years of age at the time of diagnosis of MM who had undergone upfront ASCT from
January 1, 1990, to July 31, 2007. Thirty-eight patients #40 years of age and 608 patients aged 41-65 were
identified. There was a high rate of plasma cell leukemia (PCL) in young patients at 11% compared to the
reported rate of 2%-4%. At diagnosis, there was an increased rate of renal failure in the young cohort com-
pared to patients aged 41-65 years at 25% versus 16% and Bence Jones proteinuria at 81% versus 51%. The
rate of complete or partial response was similar between the groups at 79% and 83% in the young and older
cohorts, respectively. Median PFS post-ASCTwas 22.0 months (95% confidence interval [CI]: 16.1, 28.0),
versus 26.9 months (95% CI: 24.0, 29.8) for patients aged 41-65 years (P 5 .66). Median OS from date of
ASCTwas also similar to those over 40 years: 68.1 months (95% CI: 39.0, 97.2) versus 80.7 months (95%
CI: 68.1, 93.4); P5 .90. Treatment-related mortality (TRM) was low at 2.6% and 2.3% in the young and older
cohorts, respectively. Despite previous reports that young age is a positive prognostic marker, our study
found OS post-ASCT is equivalent to those aged 41-65 years. This study emphasizes the importance of
developing strategies to better the outcomes of young patients with MM.
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Multiple myeloma (MM) is amalignant plasma cell
disorder primarily of the elderly, with a peak incidence
between 60 and 70 years of age [1,2]. It is uncommon in
persons younger than 40 years, representing only 2%of
all patients diagnosed withMM [2,3]. Younger age has
been reported to correlate with improved survival, and
has been recognized as an important prognostic factorDivision of Hematology/Oncology, Mayo Clinic Arizona,
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6/j.bbmt.2009.02.013[2,4-7]. Chromosomal patterns have been analyzed in
patients\45 years of age and compared to older co-
horts, and no significant difference between the groups
have been found, suggesting thatMMinyoungpatients
does not represent a distinct biologic entity and does
not explain the positive prognostic factor [8].
MM in young patients was initially thought to have
a more indolent course with atypical presentations
such as multiple solitary or extramedullary plasmacy-
tomas, increased osteolytic lesions, lower serum or uri-
nary monoclonal proteins, and few or no plasma cells
in the bone marrow [9-11]. However, Blade and
colleagues [3] disputed this by publishing a series of
72 patients younger than 40 years of age with MM
who had presenting features and response to therapy
similar to those reported in series of MM with older
patients. Despite the similarities, a median survival of
54 months was observed, which suggested improved
survival compared to the general MM population,
which had an overall survival (OS) of 2-3 years at
that time [12-14]. In that cohort, only 9 patients
Biol Blood Marrow Transplant 15:686-693, 2009 687Age Does Not Confer Superior Prognosis in Patients with MMunderwent autologous stem cell transplantation
(ASCT), of which only 3 had upfront ASCT. As
ASCT remains the standard of care in eligible patients
as upfront therapy, this may not reflect the true prog-
nosis of these patients undergoing this modality of
treatment.
Indeed, 2 randomized controlled trials comparing
conventional chemotherapy to high-dose chemother-
apy with ASCT rescue as initial therapy in MM have
shown improvement in event free survival (EFS) and
OS in patients under the age of 65 years [15,16].
More recently, patients younger than 50 years of age
withMMwere compared to patients 50 years and older
who underwent treatment with either conventional
chemotherapy or upfront ASCT and found that young
patients had a significantly longer survival with either
treatment modality [4].
The standard of care at our institution is to offer
upfront ASCT for all suitable patients under the age
of 65 years diagnosed with MM. Given that young pa-
tients rarely have contraindications to ASCT and may
be able to better tolerate high-dose therapy, almost all
patients #40 years of age undergo ASCT. The objec-
tive of this study is to describe presenting features and
outcomes of patients #40 years of age with MM who
undergo ASCT as first-line treatment and compare
OS and PFS to an older cohort.METHODS
Patients
Patients were identified from the Princess Mar-
garet Hospital (PMH) ASCT database. All patients
aged 40 years or less at the time of diagnosis of MM
that underwent ASCT from January 1, 1990, to August
1, 2007, were included in the study. PMH is a referral
center for peripheral hospitals, and presenting data
was used from the referring centers when available.
Only patients who underwent upfront ASCT for the
diagnosis of MM were included. Patients who had un-
dergone ASCT as salvage therapy and patients who
had received chemotherapy for smoldering myeloma
or solitary plasmacytoma were excluded from the
study. This patient group was compared to patients
aged 41-65 years who were identified by the PMH
ASCT database, and had also underwent upfront
ASCT.Criteria for a Response and Study Definitions
Response to treatment and progression were as-
sessed using the European Blood and Bone Marrow
Transplantation (EBMT) criteria [17]. Response to
transplantation was taken at the closest follow up
visit to 100 days post-ASCT. Anemia was defined
as a hemoglobin \12 g/dL; hypercalcemia definedas a corrected calcium $2.75 mmol/L; and renal
failure as a creatinine$177 mmol/L. Plasma cell leuke-
mia (PCL)was defined as the presence of.20%plasma
cells in peripheral blood and an absolute plasma cell
count more than 2  109/L [18]. Time of neutrophil
engraftment was defined as first of 2 consecutive days
with an absolute neutrophil count (ANC) .0.5 
109/L.Time of platelet engraftment was defined as first
of 3 consecutive days with platelets .20  109/L and
platelet transfusion independent for 7 days.Statistical Analysis
OS was measured from date of diagnosis and from
date of ASCT to date of last follow-up or death. PFS
was calculated for all patients from date of ASCT to
time of relapse, death, or date the patient was last known
to be in remission. Curves for OS and PFS were plotted
according to themethod of Kaplan andMeier, and were
compared to patients 41-65 years of age by the log-rank
test. For all tests, a 2-sided P-value of #.05 was cons-
idered statistically significant. Calculations were per-
formed using SPSS/PC (SPSS Inc., Chicago IL).RESULTS
Clinical and Laboratory Data
Forty-three patients aged#40 years at time of diag-
nosis of MM were identified. Five patients were ex-
cluded for undergoing salvage ASCT or ASCT .18
months from diagnosis. Thirty-eight patients were in-
cluded in the analysis. All patients identified through
the ASCT database had presented with MM requiring
treatment; none of the young patients in this study pre-
sentedwithmonoclonal protein of undetermined signif-
icance (MGUS), smoldering myeloma, or solitary
plasmacytomas thathadprogressed toMM.Themedian
agewas 37.2 years (range: 29.3-40.1 years), and23 (61%)
were males. Six hundred eight patients in the compara-
tor groupwere identifiedwith amedian age of 56.4 years
(range: 41.1-65.5 years), and 365 (60%) were males.
Table 1 shows the distribution according to the
M-protein type in young patients. A majority had
IgG MM (53%), followed by light chain (LC) MM
at 21%. The remainder of patients had IgA or IgD
MM at 18% and 8%, respectively. Four patients
(11%) had evidence of PCL at diagnosis. A majority
of patients had k LC type (74%). No patients had
evidence of systemic amyloidosis (AL).
Laboratory features at presentation of patients
#40 years of age are shown in Table 2. Sixty-seven
percent of young patients were anemic. Twenty-five
percent of young patients had renal failure at time of
diagnosis compared to 16% in the older cohort. The
rate of hypercalcemia was similar in the young and
older cohorts at 23% and 22%, respectively. The
Table 1. CharacteristicsofPatients#40YearsofAgewithMM
Characteristic
Age—year
Median 37.2
Range 29.3-40.1
Males—no. of patients (%) 23 (61)
Monoclonal protein—no.of pts (%) Light chains
k l
IgG 20 (53) 17 3
Light chain 8 (21) 4 4
IgA 7 (18) 6 1
IgD 3 (8) 1 2
Plasma cell leukemia—no. of patients (%) 4 (11)
MM indicates multiple myeloma.
Table 3. ASCT Parameters of Patients #40 Years of age
Factor
No. of
Patients (%) Median Range
First line induction therapy (n 5 38)
VAD 25 (66) 4 cycles 2-7
Dexamethasone on a VAD schedule 5 (13)
Melphalan and Prednisone 5 (13)
Patients receiving $2 lines of
induction therapy (n 5 38)
16 (42)
Patients that progressed while waiting
for ASCT (n 5 38)
5 (13)
Cyclophosphamide and
G-CSF mobilization (n 5 36)
33 (87)
Conditioning Regimen (n 5 38)
Melphalan 200 mg/m2 24 (63)
Melphalan, VP16, ±TBI 10 (26)
Busulfan and cyclophosphamide 4 (11)
Type of SCT (n 5 38)
Peripheral blood 37 (97)
Peripheral blood + bone marrow 1 (3)
CD34+  106 cells/kg (n 5 29) 7.52 3.0-73.3
Time to ASCT from diagnosis,
months (n 5 38)
8.5 4.8-17.9
VAD indicates vincristine, adriamycin, and dexamethasone; ASCT, auto-
logous stem cell transplantation; SCT, stem cell transplantation; G-CSF,
granulocyte-colony stimulating factor; TBI, total body irradiation.
*2 pts had planned Melphalan and Prednisone followed by VAD.
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rable at 72% in the young cohort and 74% in the older
cohort. Bence Jones proteinuria was more common in
the younger cohort at a rate of 81% compared to 51%
in the older cohort. Amajority of young patients (76%)
and older patients (74%) had radiologic evidence of
bone disease at diagnosis. In patients #40 years of
age, 3 patients (8%) presented with spinal cord com-
pression, and 16 (42%) patients underwent palliative
radiation for bone disease prior to ASCT. Of the 21
patients in the young cohort that staging according
to the International Staging System (ISS) could be ob-
tained, 48% of patients were stage 1 at diagnosis. Ten
young patients had cytogenetics reported, of which 9
had abnormal cytogenetics. Three patients had dele-
tion of chromosome 13, 3 had t(11;14), and 1 patient
had both.Table 4. Response Rates in Patients with MM Undergoing
Upfront ASCTTransplantation
Details of the transplantation for patients aged
#40 years of age are summarized in Table 3. As induc-
tion chemotherapy, 66% of patients received vincris-
tine, adriamycin, and dexamethasone (VAD), with
a median of 4 cycles (range: 2-7), 13% received high-
dose dexamethasone alone on a VAD schedule, and
13% received melphalan and prednisone (MP). Two
patients received both MP and VAD as initial therapy.
Eighty-seven percent of patients received cyclo-
phosphamide (Cy) and granulocyte-colony stimulat-Table 2. Laboratory Data at Time of Diagnosis of MM in
Patients #40 Years of Age
Factor
No. of
Patients Median Range Limit
Hemoglobin (g/dL) 33 10.4 39-147 <12, 67%
Calcium (mmol/L) 31 2.45 1.99-3.67 $2.75, 23%
Creatinine (mmol/L) 32 93 53-894 $177, 25%
Bone marrow plasma cells (%) 32 65 4-100 $30%, 72%
Albumin (g/L) 24 39.5 22-48 <38, 38%
b-2-microglobulin (mmol/L) 20 172 31-1100 >300, 20%
Bence Jones protein 31 Present, 81%
MM indicates multiple myeloma.ing factor (G-CSF) as mobilizing agents. Sixty-three
percent of patients were conditioned with melphalan
(Mel) 200 mg/m2 in either 1 dose or 2 doses of 100
mg/m2. Twenty-six percent of patients received Mel
160 mg/m2, VP16 60 mg/kg, 6 total body irradiation
(TBI), and 11% received busulfan (Bu) and Cy at a to-
tal dose of 14 mg/m2 and 120 mg/kg, respectively, as
part of the Cell Pro Study [19]. All patients received
peripheral blood stem cells (PBSCs), with 1 patient re-
ceiving bone marrow stem cells in addition to their
PBSCs. Median infused CD341 cell dose was 7.52 
106 cells/kg (range: 3-73.3). Median time to ASCT
from date of diagnosis was 8.5 months (range: 4.8-
17.9 months). Eleven percent of patients had a com-
plete remission (CR) after first-line induction that in-
creased to 13% at the time of ASCT, and 55% had
a partial remission (PR) following induction, which
also increased to 63% at the time of ASCT Table 4.# 40 Years, n 5 38 (%)
41-65 Years,
n 5 192 (%)
Response
Following First
Induction Treatment
Status Prior
to ASCT Post-ASCT Post-ASCT
CR 4 (11) 5 (13) 11 (29) 33 (17)
PR 21 (55) 24 (63) 19 (50) 126 (66)
MR 7 (18) 7 (18) 2 (5) 4 (2)
SD 3 (8) 2 (5) 3 (8) 15 (8)
PD 3 (8) 0 2 (5) 8 (4)
MM indicates multiple myeloma, ASCT, autologous stem cell transplan-
tation; CR, complete response; PR, partial response; MR, minimal
response; SD, stable disease; PD, progressive disease.
Figure 1. Kaplan-Meier estimates of OS in patients with MM #40
years of age compared to patients aged 41-65 years who underwent up-
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ASCT. Median time to neutrophil engraftment was
11 days (range: 9-18 days), and median time to platelet
engraftment was 11 days (range: 6-15 days). One pa-
tient failed to engraft platelets, and 2 patients’ platelets
never fell below 20  109/L. Of the 22 patients in
which transfusion data was available, 41% and 55% re-
quired packed red blood cells (PRBC) and platelet
transfusions, respectively. Median PRBC transfusions
was 2 units (range: 2-4), and median platelet transfu-
sions was 5 units (range: 5-15). The rate of febrile neu-
tropenia was 82% (28 of 34 patients). Median length of
hospital admission from date of ASCT was 15 days
(range: 11-43 days).
Post-ASCT, 49%of patients receivedmaintenance
therapy. Regimens varied from combinations of inter-
feron, prednisone, dexamethasone, and thalidomide.
Five (13%) of the patients went on to tandem ASCT.front ASCT.
Figure 2. Kaplan-Meier estimates of PFS in patients with MM #40
years of age compared to patients aged 41-65 years who underwent up-
front ASCT.Relapse and Survival
Themedian time to best response following ASCT
was recorded at 3 months post-ASCT (range: 31-152).
Table 4 illustrates response rates post ASCT. In the
young cohort, 29% achieved a CR, 50% a PR, 5%
a minimal response (MR), 8% had stable disease
(SD), and 5% had progressive disease (PD). Following
tandem ASCT, 1 patient with MR and 1 patient with
PR obtained a CR. Seventeen percent of patients
aged 41-65 achieved a CR, 66% a PR, 2% an MR,
8% had SD, and 4% had PD.
The median duration of follow-up among survi-
vors was 53 months (range: 12-198 months). Table 6
displays study outcomes. Median OS from date of di-
agnosis in patients #40 years of age was 81.4 months
(95% CI: 49.0, 113.1). Although there was a trend to
shortened survival, there was no difference in median
OS from date of ASCT when patients #40 years of
age were compared to the cohort of patients 41-65
years of age (68.1 months [95% CI: 39.0, 97.2] versus
80.7 months [95% CI: 68.1, 93.4], P 5 .90), nor was
there a difference in median PFS from date of ASCT
(22.0 months [95% CI: 16.1, 28.0] versus 26.9
months [95% CI: 24.0, 29.8]; P 5 .66) (Figures 1
and 2). The actuarial survival of patients #40 years
of age at 5 and 10 years from date of ASCT was 60%
and 43%, respectively, and PFS at 5 and 10 years was
31% and 25%, respectively.
Subgroup analysis, revealed that, although not
statistically significant, there was a trend to improved
median OS of patients #40 years of age with ISS
stage 1 at diagnosis compared those .1 (85.6 versus
33.4 months; P 5 .22). There was no statistically
significant difference in median OS from date of
ASCT if young patients were either in CR or PR
post-ASCT compared to MR, SD, and PD (79.0
versus 42.6 months; P 5 .20), whereas those youngpatients that achieved CR or PR post-ASCT appreci-
ated a statistically significant longer PFS (30.9 versus
8.0 months, P 5 .02).
One patient #40 years of age died from sepsis
within 100 days of ASCT, yielding a treatment-related
mortality (TRM) of 2.6%. The older cohort experi-
enced a similar TRM, with 14 deaths within 100 days
of ASCT (2.3%). Main causes of death in the young
cohort were from PD and infection (Table 7).DISCUSSION
This is the first series to report that very young
patients with MM undergoing upfront ASCT do not
have superior prognosis compared to an older cohort.
All patients in this study presented with MM without
Table 5. Safety Endpoints in Patients #40 years of Age with
MM Undergoing Upfront ASCT
Endpoint
No. of
Patients (%) Median Range
Neutrophil engraftment (n 5 32) 32 (100) 11 days 9-18
Platelet engraftment (n 5 31) 30 (97) 11 days 6-15
PRBC transfusions (n 5 22) 9 (41) 2 units 2-4
Platelet transfusions (n 5 22) 12 (55) 5 units 5-15
Febrile Neutropenia (n 5 34) 28 (82)
Days of hospitalization (n 5 35) 15 11-43
MM indicates multiple myeloma; PRBC, packed red blood cells; ASCT,
autologous stem cell transplantation.
Table 7. Causes of Death in 38 Patients#40 Years of Agewith
MM
Cause No. of Patients
Myeloma progression 7
Infection 5
Aspiration pneumonia 1
Hemorrhagic cystitis/renal failure 1
Pulmonary and brain hemorrhages 1
Unknown 2
MM indicates multiple myeloma.
690 Biol Blood Marrow Transplant 15:686-693, 2009P. K. Cheema et al.a prior plasma cell disorder. Presenting features of ane-
mia and hypercalcemia in this patient population were
comparable to the general population with MM [2]
and to reported rates in patients\40 years of age [3].
In our study, IgG MM was found in more than half
the patients, which again, is consistent with the general
MM population; however, as previously reported in
young patients, LC MM occurred at a higher rate
than IgA MM, unlike the older population, and there
was an increase in IgD MM at 8% compared to re-
ported rate of 2% [20,21]. IgD MM has been com-
monly associated with renal failure, and a majority
have Bence Jones proteinuria [22]; only 1 of the 3 pa-
tients with IgD MM had renal failure at diagnosis,
but all had Bence Jones proteinuria. Chromosome 13
deletion, a common chromosomal abnormality in
MM that has been associated with shortened PFS
following ASCT [23], was found in one-third of our
patients, again similar to the reported rate in various
age groups [8].
Despite the similarities to the general MMpopula-
tion, a few clinical parameters suggest that MM in
young patient may present more aggressively. There
was a high rate of Bence Jones proteinuria at 81%,
and a high rate of renal failurewith 25%of patients hav-
ing a creatinine$177 mmol/L. The rate of renal failure
was similar to the report by Blade and colleagues inTable 6. Study Outcomes
Endpoint
#40 Years
Months (95% CI)
n 5 38
41-65 Years
Months (95% CI)
n 5 608 P-Value
Median OS from
date of diagnosis
81.4 (49.0, 113.1)
Median OS from ASCT 68.1 (39.0, 97.2) 80.7 (68.1, 93.4) .9
Median PFS from ASCT 22.0 (16.1, 28.0) 26.9 (24.0, 29.8) .66
Median OS from ASCT
CR + PR (n 5 30) 79.0 (51.4, 106.6) .2
MR, SD, PD (n 5 7) 42.6 (0, 88.6)
Median PFS from ASCT
CR+PR (n 5 30) 30.9 (5.2, 56.5) .02
MR, SD, PD (n 5 7) 8.0 (5.2, 10.9)
ASCT indicates autologous stem cell transplantation; OS, overall
survival; PFS, progression free survival; CR, complete response; PR, par-
tial response; MR, minimal response; SD, stable disease; PD, progressive
disease; CI, confidence interval.patients\40 years of age [3], but higher than those
aged 41-65 years in our series at 16% and previously re-
ported in patients younger than 50 years of age at 15%
[4]. There was also an increased risk of PCL at 11%
compared to the reported incidence of 2%-4% [24-
26]. Although 76% of our young patients had radio-
logic evidence of bone disease at diagnosis, which is
comparable to the rate of 79% found in the general
MM population [2], there was a high rate of spinal
cord compression at presentation at 8%. These differ-
ences may simply suggest a delay in diagnosis of young
patients withMMorhighlights the aggressive nature of
this disease in young patients.
We report a 79% combined CR and PR rate fol-
lowing ASCT in young patients. This appears to be
similar to response rates reported in the literature fol-
lowing ASCT in patients\65 years of age with MM
(81%-86.6%) [15,16], and similar to patients in this se-
ries aged 41-65 years. However, in our study there did
appear to be a slightly higher rate of CR in the younger
cohort. Although clinical response is desirable and is
commonly considered an important prognostic indica-
tor for survival [15], neither the rapidity nor degree of
response have reliably predicted survival [27,28]. Our
study found that although young patients with CR
and PR appreciated a statistically significant longer
PFS, a statistically significant OS difference was not
found. However, there was a trend toward improved
survival in patients achieving a CR and PR, which is
in keeping with previous reports.
Following ASCT in patients withMM\65 years of
age the median OS from date of diagnosis has been re-
ported at 54.1 to 56months [15,16].We report amedian
OS of 81 months in patients#40 years of age; although
this OSmay suggest that patients#40 years of age have
improved survival, when compared to the patients 41-65
years of age in our study, there was no significant differ-
encebetween the2groups. In a recent studyof outcomes
in patients\50 years of age compared to patients $50
yearsof ageundergoingupfrontASCTforMM,a signif-
icantly longer survival of 90months in the young cohort
opposed to 68.4months in the$50 age groupwas found
[4].When they specifically looked at patients\40 years
of age, the relative survival was similar to that of patients
\50 years of age at 87.6 months. This discrepancy with
our study may be explained by worse outcomes in our
Biol Blood Marrow Transplant 15:686-693, 2009 691Age Does Not Confer Superior Prognosis in Patients with MMyoung population compared to their cohort. Our study
did include patients with de novo PCL, which has
been associated with worse prediction of survival and
poor response rates [22,29]; the rate of PCL in the afore-
mentioned study was not reported. Alternatively, given
that the 10 year actuarial survival in the young cohort
undergoing upfront ASCTwas identical in both studies
at 43%, may indicate that our older cohort aged 41-65
years had improved outcomes compared to their com-
parator group.
The lack of increasedOS in younger patients in our
study was also seen in PFS. The patients in our study
experienced less than 2 years of PFS post-ASCT.
EFS from diagnosis of MM has been reported at 27
to 32 months in patients\65 years of age that undergo
upfront ASCT [15,16]. Unfortunately, despite their
young age, PFS was no different to those patients 41-
65 years of age transplanted or followed at our institu-
tion. It is possible that with the introduction of upfront
ASCT it has eliminated the OS and PFS advantage
between the 2 groups.
Modalities to lengthen OS and PFS are required in
this young patient population. Maintenance therapy
was used in only half the patients following ASCT. Al-
though, the role of maintenance therapy is controversial
because it has not consistently shown improvement in
PFS or OS [30-34], it may be an option for those that
did not achieve a good response following ASCT.
Several randomized trials investigating tandem ASCT
have shown to improve OS and EFS [35-38], and only
5 patients in this study had received this treatment.
Also, autologous transplantation followed by dose-re-
duced allogeneic stem cell transplantation has shown
to be safe and increase CR rates [39-41]; however, im-
provement in EFS andOS compared to tandem autolo-
gous transplantation has shown contradictory results in
randomized controlled trials [41-43]. Finally, promising
newer agents such as thalidomide, lenalidomide, and
bortezomib are changing frontline therapy in the con-
text of ASCT. Thalidomide, in combination with dexa-
methasone, yielded superior response and very good PR
(VGPR) rates compared to dexamethasone-based regi-
mens [44-48]. Compared to VAD, bortezomib plus
dexamethasone also significantly improved the rate of
CR/VGPR before ASCT at 47%, and after ASCT at
62% [49]. There is limited data with the use of lenalido-
mide as front-line therapy in ASCT eligible patients;
a small pilot study of lenalidomide plus dexamethasone
in newly diagnosed patients showed an overall response
rate of 91% with 56% obtaining CR/VGPR [50].
However, it is too early to determinewhether this better
tumor reduction after induction treatment with novel
agents will translate into longer PFS and OS, particu-
larly in this very young population that appears to
present with aggressive features. Subgroup analysis or
new studies to establish the role and benefit of these
novel agents in very young patients is needed.Our study confirmed that upfront ASCT in patients
#40 years of age is safe, with a lowTRMat 2.6%,which
is comparable to the older cohort in this study and to the
reported rate of 2%-4% [15,16]. Results of ASCT have
improved largely through reduction of TRM using
modern supportive care, including mobilized PBSCs
in place of marrow and preparation with Mel rather
than radiation-containing regimens [51-53]. Other
safety parameters such as days to engraftment, number
of transfusions required, and febrile neutropenia rates
did not differ from those reported in the literature for
the general MM population undergoing ASCT.
ISS for MM has been validated to provide useful
prognostic groupings in variety of situations including
those patients \65 years [54]. Younger patients are
more likely to have ISS stage 1 at diagnosis compared
to the older cohorts [4], and in our study, almost half of
our young patients were found to be in this stage. Also,
it has been reported that patients\40 years of age with
MM that have b2-microglobulin levels\2.7mg/L that
would fall in either ISS stage I or II based on albumin
levels have a significantly longer survival than those
with higher levels [3]. Our study reports a strong trend
toward improved OS in patients#40 years of age with
stage 1 disease at 86 months versus 33 months in those
with stages 2 or 3 disease. Although not statistical sig-
nificance, this may have been a reflection of the small
numbers in this study, or may indeed indicate unique-
ness of very young patients with this disease.
A limitation to this study is that all patients identi-
fied by the ASCT database presented withMM requir-
ing treatment and went on to ASCT. This may
represent patients with more aggressive disease at pre-
sentation. This study is also somewhat limited by the
number of patients included, although MM under
the age of 40 years is very uncommon, and very few se-
ries in this age group have been reported.
This study found that patients aged 40 years and
under with MM present with advanced disease, as evi-
denced by a high rate of PCL, renal failure, and pro-
teinuria. Upfront ASCT is safe, and yields high
response rates in young patients; however, despite re-
ports that young age is a positive prognostic marker,
PFS post-ASCT is \2 years, and the median OS is
only 5.7 years, which is equivalent to those aged 41-
65 years. It is possible that upfront ASCT in the older
cohort has eliminated this prognostic advantage for
those 40 years of age or younger. Although these find-
ings need to be confirmed by large randomized con-
trolled trials, we conclude that the need for more
aggressive and safe treatments are warranted to im-
prove survival in this young patient population.ACKNOWLEDGMENTS
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